"They have all failed for varying reasons."
Thanks, Rona, I appreciate your comments and fairness in identifying CGB in its sector, and I agree that there are failures upon failures in all Pennies, which is why they say that nearly 100% of Pennies eventually fail if they cannot succeed with their business models. I also believe that if you are not aware of the high risks, at this end of town, you should not swim in the pool. My goodness, just look at the crazy ride with crypto.
So can I ask, just some reasonable points of discussion for your thoughts:
1. Are you possibly suggesting, or perhaps you feel, that the failure of this company to raise the share price is solely due to the failures of management to deliver, and is not in any way influenced directly or indirectly, as a result of the COVID pandemic, the current Ukraine Crisis, the Australian/China trade debacle, the 2018/19 drought, which made it hard for T12 to have consistency in the delivery of raw stock, and the Long suspension and the delays in the role out of Cannabis legislation? Do you feel that CGB was alone in suffering through the impact of those past and ongoing external events? I am just curious, that is all?
2 ) Is being listed with 10ML in the bank, or thereabouts, with the delivery of Canntab, Fusspot, the research with M.S., and the Thailand Hemp/Cannabis investment program, plus the roll-out of a new product range under the Grassroots label all evidence of a Microcap company failing to articulate its vision moving forward for the next financial year?
"No, I'm not commenting on the webcast at all. I'm saying post the suspension they have had close to 3 years to deliver on their business plan that was put forward in the prospectuses"
With all due respect, I think you should have included that in your comments as Canntab was part of the Prospectus and Dedi Meiri's Cannabinoid finds as well, now back in the hands of the company here in Australia.
Expand
